Patents by Inventor Matthias Heinrich Nettekoven

Matthias Heinrich Nettekoven has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEW INDOLE OR BENZIMIDAZOLE DERIVATIVES AS CB1 INVERSE AGONISTS
    Publication number: 20080234290
    Abstract: Provided are compounds of the formula I: and pharmaceutically acceptable salts thereof, processes for making said compounds and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising said compound and pharmaceutically acceptable salts thereof, and methods of using said compounds. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.
    Type: Application
    Filed: May 2, 2008
    Publication date: September 25, 2008
    Inventors: Konrad Bleicher, Matthias Heinrich Nettekoven, Philippe Pflieger, Stephan Roever
  • Benzoyl-piperazine derivatives
    Patent number: 7427612
    Abstract: A compound of formula wherein the substituents are as described in the specification for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
    Type: Grant
    Filed: September 2, 2004
    Date of Patent: September 23, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Daniela Alberati-Giani, Synese Jolidon, Robert Narquizian, Matthias Heinrich Nettekoven, Roger David Norcross, Emmanuel Pinard, Henri Stalder
  • Indole or benzimidazole derivatives as CB1 inverse agonists
    Patent number: 7384945
    Abstract: Provided are compounds of the formula I: and pharmaceutically acceptable salts thereof, processes for making said compounds and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising said compound and pharmaceutically acceptable salts thereof, and methods of using said compounds. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.
    Type: Grant
    Filed: October 25, 2005
    Date of Patent: June 10, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Konrad Bleicher, Matthias Heinrich Nettekoven, Philippe Pflieger, Stephan Roever
  • BENZOYL-PIPERAZINE DERIVATIVES
    Publication number: 20080119486
    Abstract: The invention relates to compounds of formula wherein the substituents are described herein. The compounds may be used in the treatment of illnesses based on the glycine uptake inhibitor, such as psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
    Type: Application
    Filed: October 31, 2007
    Publication date: May 22, 2008
    Inventors: Synese Jolidon, Robert Narquizian, Matthias Heinrich Nettekoven, Roger David Norcross, Emmanuel Pinard, Henri Stalder
  • Thiazole derivatives
    Patent number: 7371751
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof, for use as therapeutically active substances. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors, including obesity.
    Type: Grant
    Filed: December 3, 2004
    Date of Patent: May 13, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Matthias Heinrich Nettekoven, Stephan Roever
  • Indole derivatives as H3 inverse agonists
    Patent number: 7361682
    Abstract: The present invention relates to compounds of formula I: wherein X, R1, R2, R3, R4 and R5 are as defined in the description and claims, and pharmaceutically acceptable salts thereof, to the preparation of such compounds and pharmaceutical compositions containing them. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
    Type: Grant
    Filed: June 20, 2005
    Date of Patent: April 22, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Silvia Gatti McArthur, Cornelia Hertel, Matthias Heinrich Nettekoven, Susanne Raab, Olivier Roche, Rosa Maria Rodriguez-Sarmiento, Franz Schuler, Jean-Marc Plancher
  • Benzoyl-piperazine derivatives
    Patent number: 7319099
    Abstract: The invention relates to compounds of formula wherein the substituents are described herein. The compounds may be used in the treatment of illnesses based on the glycine uptake inhibitor, such as psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
    Type: Grant
    Filed: August 4, 2004
    Date of Patent: January 15, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Synese Jolidon, Robert Narquizian, Matthias Heinrich Nettekoven, Roger David Norcross, Emmanuel Pinard, Henri Stadler
  • Pyrazinecarboxamide derivatives as CB1 antagonists
    Publication number: 20070293509
    Abstract: The present invention relates to compounds of the formula I: wherein R1 to R8 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors, such as obesity.
    Type: Application
    Filed: May 30, 2007
    Publication date: December 20, 2007
    Inventors: Paul Hebeisen, Hans Iding, Matthias Heinrich Nettekoven, Ulrike Obst Sander, Stephan Roever, Urs Weiss, Beat Wirz
  • Piperidinyl pyrimidine derivatives
    Publication number: 20070281921
    Abstract: The present invention relates to compounds of formula I and their pharmaceutically acceptable salts wherein formula I is: wherein X, Y, Z, R1 and R2 are as defined in the description and claims. The compounds of the present invention act as antagonists and/or inverse agonists at the histamine 3 receptor and are useful for the treatment and/or prevention of diseases such as obesity, metabolic syndrome (syndrome X), and other eating disorders.
    Type: Application
    Filed: May 21, 2007
    Publication date: December 6, 2007
    Inventors: Matthias Heinrich Nettekoven, Olivier Roche
  • IH-indol-5-YL-piperazin-1-YL-methanone derivatives
    Publication number: 20070270423
    Abstract: The present invention relates to compounds of formula I and their pharmaceutically acceptable salts wherein in formula I is: wherein R1 to R4 are as defined in the description and claims. The compounds of the present invention are useful for the treatment and/or prevention of diseases which are associated with the modulation of histamine 3 (H3) receptors.
    Type: Application
    Filed: April 26, 2007
    Publication date: November 22, 2007
    Inventors: Matthias Heinrich Nettekoven, Olivier Roche
  • Benzothiazolyl derivatives
    Patent number: 7297707
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3 R3a and R3b are as provided in the description, and pharmaceutically acceptable salts thereof, for use in the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors such as obesity.
    Type: Grant
    Filed: June 18, 2004
    Date of Patent: November 20, 2007
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Matthias Heinrich Nettekoven, Stephan Roever
  • Thiazole derivatives
    Patent number: 7265109
    Abstract: Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein the substituents have the significance given in the specification, and the compounds are neuropeptide Y(NPY) antagonists which are useful in the treatment of obesity.
    Type: Grant
    Filed: August 10, 2004
    Date of Patent: September 4, 2007
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Werner Neidhart, Matthias Heinrich Nettekoven, Philippe Pflieger, Sven Taylor
  • Neuropeptide Y antagonists
    Patent number: 7265125
    Abstract: Quinoline and quinazoline derivatives can be used in the form of pharmaceutical preparations as Neuropeptide Y antagonists for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.
    Type: Grant
    Filed: April 7, 2005
    Date of Patent: September 4, 2007
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Volker Breu, Frank Dautzenberg, Philippe Guerry, Matthias Heinrich Nettekoven, Philippe Pflieger
  • Naphthaline derivatives as H3 inverse agonists
    Patent number: 7259158
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, to the preparation of such compounds and pharmaceutical compositions containing them. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
    Type: Grant
    Filed: June 1, 2005
    Date of Patent: August 21, 2007
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Silvia Gatti McArthur, Cornelia Hertel, Matthias Heinrich Nettekoven, Jean-Marc Plancher, Susanne Raab, Olivier Roche, Rosa Maria Rodriguez-Sarmiento, Franz Schuler
  • Aminothiazole derivatives
    Patent number: 7253197
    Abstract: Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R4 have the significance given in the specification, and the compounds, salts and esters can be used for the treatment of obesity.
    Type: Grant
    Filed: August 5, 2003
    Date of Patent: August 7, 2007
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Wolfgang Guba, Patrizio Mattei, Werner Neidhart, Matthias Heinrich Nettekoven, Philippe Pflieger
  • Thiazole derivatives
    Patent number: 7250431
    Abstract: Thiazole derivatives of formula I are provided as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R5, a and b have the significance given in the specification. The compounds are neuropeptide Y Y5 receptor antagonists which can be used for the treatment of obesity.
    Type: Grant
    Filed: August 10, 2004
    Date of Patent: July 31, 2007
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Werner Neidhart, Matthias Heinrich Nettekoven, Philippe Pflieger
  • Pyridine-3-carboxamide derivatives as CB1 inverse agonists
    Patent number: 7229999
    Abstract: The present invention relates to compounds of the formula wherein X and R1 to R8 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors, such as obesity.
    Type: Grant
    Filed: April 4, 2006
    Date of Patent: June 12, 2007
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Paul Hebeisen, Hans Iding, Matthias Heinrich Nettekoven, Ulrike Obst, Stephan Roever, Beat Wirz
  • Quinazoline derivatives
    Patent number: 7205309
    Abstract: Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3 and A have the significance given in the specification are provided. The compounds can be used for the treatment or prevention of obesity.
    Type: Grant
    Filed: July 3, 2003
    Date of Patent: April 17, 2007
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Patrizio Mattei, Werner Mueller, Werner Neidhart, Matthias Heinrich Nettekoven, Philippe Pflieger
  • Quinoline derivatives
    Patent number: 7166589
    Abstract: Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3, A1 and A2 have the significance given in claim 1, can be used in the form of pharmaceutical preparations for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.
    Type: Grant
    Filed: March 16, 2006
    Date of Patent: January 23, 2007
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Michael G. Klug, Patrizio Mattei, Werner Mueller, Werner Neidhart, Matthias Heinrich Nettekoven, Philippe Pflieger, Jean-Marc Plancher
  • Quinoline derivatives
    Patent number: 7064134
    Abstract: Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3, A1 and A2 have the significance given in claim 1, can be used in the form of pharmaceutical preparations for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: June 20, 2006
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Michael G. Klug, Patrizio Mattei, Werner Mueller, Werner Neidhart, Matthias Heinrich Nettekoven, Philippe Pflieger, Jean-Marc Plancher